Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDT assessment

This article was originally published in The Gray Sheet

Executive Summary

Photodynamic therapy for wet age-related macular degeneration should be used only for individuals with entirely classic subfoveal choroidal neovascularization and visual acuity of 6/60 or better, UK's National Institute for Clinical Excellence says in Oct. 14 appraisal consultation document. The paper further recommends that PDT be "used in predominantly (but not entirely)" classic CNV associated with wet AMD only as part of ongoing or new clinical trials designed to generate relevant outcome data, including data on quality of life and costs. CMS announced in March that available data were "not adequate" to grant coverage of an off-label occult-only indication...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT017342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel